摘要
目的:观察扶正防癌方联合化疗对晚期结肠癌患者生活质量及免疫功能的影响。方法:将符合入选标准的66例患者随机分为治疗组和对照组,对照组给予FOLFOX4方案化疗和对症支持治疗,治疗组在上述治疗的基础上使用FZFA,比较2组患者近期客观有效率、稳定率和生活质量;2组患者外周血CD4+T淋巴细胞中Th17/Treg细胞百分比及比值;以及2组人血液炎性细胞因子表达水平。结果:2组患者近期客观有效率、稳定率和生活质量改变,患者外周血CD4+T淋巴细胞中Th17/Treg细胞百分比及比值,以及外周血以及炎性细胞因子表达水平均有统计学意义(P<0.05)。结论:扶正防癌方联合化疗药物和单纯化疗药物对晚期结肠癌患者均可改善免疫功能,减轻不良反应,提高生活质量,但前者明显优于后者。
Objective： To observe the effect of FZFA combined with chemotherapy on life quality and immune function of advanced colorectal cancer patients. Methods： Sixty six patients were randomly divided into treatment group and control group. Patients in the control group were given FOLFOX4 chemotherapy and supportive treatment,and the treatment group using FZFA based on the above treatment. We compared two groups of patients with recent objective efficient and stable rate and quality of life; the percentage of Th17 / Treg cells and the ratio of CD4＋T lymphocyte and inflammatory cytokines expression levels in blood of the two groups.Results： The objective response and stable rate and quality of life changes,the percentage of Th17 / Treg cells and the ratio of CD4＋T lymphocytes in peripheral blood of the two groups,and the expression of peripheral blood and inflammatory cytokine levels had significant difference（ P 0. 05）. Conclusion： FZFA combined with chemotherapy and chemotherapy for advanced colorectal cancer patients can improve immune function,alleviate the adverse reaction,improve the quality of life,but the former is obviously better than the latter.
出处
《世界中医药》
CAS
2015年第2期209-211,215,共4页
World Chinese Medicine
基金
国家自然科学基金"基于‘肺与大肠相表里’理论的肺肠同源发生的分子生物学机制研究"(编号:81273614)
